Alnylam Pharmaceuticals, Inc, a leading RNAi therapeutics company, announced that it has submitted an investigational new drug application to the US FDA for ALN-VSP, an RNAi therapeutic for the treatment of liver cancers, including hepatocellular carcinoma and other solid tumours with liver involvement.
The details can be read here.
No comments:
Post a Comment